Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital, Basel, Switzerland
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
male patients who have been tested positive for SARS-CoV2 at University Hospital Basel, Switzerland or in the near surroundings more than 10 days before enrolment
18-60 years of age
asymptomatic (thus successfully overcome COVID-19) \>14 days back
two consecutive naso-pharyngeal swabs tested negative for quantitative PCR-test for SARS-CoV-2 prior to plasma donation to demonstrate infection Resolution, or more than 28 days asymptomatic after SARS-CoV2 infection
Body weight of at least 50 kg
donor eligibility criteria according to the Swiss Red Cross Blood Transfusion Service as for regular blood donation
SARS-CoV-2 infection confirmed by PCR in respiratory secretions (naso- pharyngeal swab, broncho-alveolar lavage, sputum)
hospitalized
pulmonary infiltrates compatible with COVID-19 on CT-scan
availability of blood group compatible convalescent plasma
signed informed consent
You may not be if
Female donors are excluded from plasma donation
Treatment with Actemra® (Tocilizumab) in the course of COVID-19
Current hospitalization
Current or previous relevant medical conditions that pose a risk for the donor
Clareo Health | Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19
